Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures

NCT01147003 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01147003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01147003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2010
Completion date
September 30, 2011
Enrollment
93 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

partial onset seizures